Clear Solid — MRD surveillance for solid tumours.
Molecular residual disease surveillance after curative-intent treatment for solid cancers.
Clear Solid is molecular residual disease surveillance for solid tumours after curative-intent treatment (surgery, radiotherapy, and/or systemic therapy). It watches for trace ctDNA — the earliest molecular sign that a solid cancer may be returning.
What Clear Solid gives you
Tumour-informed MRD surveillance — designed around the specific mutations found in your own tumour for higher sensitivity.
- Tumour-informed monitoring: Tuned to your specific cancer's mutations
- Simple blood draw: Non-invasive surveillance after curative treatment
- Scheduled results in context: Each result read against your baseline
- KPCIRC clinician review: A clear plan if a signal appears
Tuned to your specific cancer.
The most sensitive MRD approach is tumour-informed — designed around the specific mutations found in your own tumour.
🧬 Why tumour-informed matters
Where a molecular baseline exists (for example from a Signature test), Clear Solid can track exactly the right signals. This improves the odds of catching a true return early while limiting false alarms.
Three things, with a clear plan.
Scheduled surveillance results, clinician review, and a plan for what happens next.
Scheduled Surveillance Results
Results delivered in context — each result read against your baseline and history, not in isolation.
KPCIRC Clinician Review
Any change in your molecular signal triggers a KPCIRC clinician review — not an automated alarm.
Clear Plan for Next Steps
A clear plan for what happens if a signal appears — including prompt imaging and next-step options.
Honest limits. As with all MRD testing, sensitivity depends on how much ctDNA a tumour sheds; a negative result reduces but does not eliminate the possibility of residual disease. Clear Solid is a complement to — not a replacement for — your scans and specialist review.
The words you will see, in plain language.
Clear Solid is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →